| __timestamp | AstraZeneca PLC | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 11606000000 |
| Thursday, January 1, 2015 | 11451000000 | 10313000000 |
| Friday, January 1, 2016 | 9739000000 | 9762000000 |
| Sunday, January 1, 2017 | 10543000000 | 9830000000 |
| Monday, January 1, 2018 | 10362000000 | 10102000000 |
| Tuesday, January 1, 2019 | 11848000000 | 10615000000 |
| Wednesday, January 1, 2020 | 11693000000 | 8955000000 |
| Friday, January 1, 2021 | 15680000000 | 9634000000 |
| Saturday, January 1, 2022 | 18955000000 | 10042000000 |
| Sunday, January 1, 2023 | 18025000000 | 10504000000 |
| Monday, January 1, 2024 | 20532000000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AstraZeneca PLC and Merck & Co., Inc. have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses surged by approximately 35%, peaking in 2022. This reflects their aggressive market expansion and strategic investments. In contrast, Merck's expenses remained relatively stable, with a slight decline of about 10% over the same period, indicating a more conservative approach. Notably, AstraZeneca's expenses consistently surpassed Merck's, highlighting their differing operational strategies. These insights provide a window into how these pharmaceutical giants allocate resources to maintain their market positions and drive growth.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited